Clinical Trial

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2026 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
Trial Details
NCT Number NCT07364422
Lead Sponsor Onconic Therapeutics Inc.
Conditions Gastric Cancer (GC)
Enrollment 49 participants
Start Date 2026-02-27
Primary Completion 2026-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-23